Figure 4
Differentiation between compounds with high risk (E4301) and low risk (ranolazine) for arrhythmia in hiPSC-CMLP with 5% hCF microtissues. (A) Representative Vm traces from a microtissue (exposed to DMSO vehicle) before and after exposure to E4031 (0 µM and 2 µM, respectively). EADs are marked with red stars. (B,C) Scatter plot (B) and cumulative probability (C) of APD80 (n = 33 microtissues per group). Values shown by lines in (B) are means ± SD, and APs with EADs are displayed with red stars. 0 μM control was significantly different from each group (vs. no EAD-blue and vs. EAD-red, *p < 0.05). (D) Representative Vm traces from a microtissue before and after exposure to a therapeutic dose (2 μM) of ranolazine. (E,F) Scatter plot (E) and cumulative probability plot (F) for APD80 (n = 31). Values shown by lines in (E) are means ± SD. APD was not significantly different between any doses of ranolazine.
